Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.80 |
| ▸ | PDE6D | O43924 | 1/20 | 0.47 |
| ▸ | PDE6A | P16499 | 1/20 | 0.47 |
| ▸ | PDE6G | P18545 | 1/20 | 0.47 |
| ▸ | PDE6B | P35913 | 1/20 | 0.47 |
| ▸ | PDE6C | P51160 | 1/20 | 0.47 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211000 | 0.89 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16401770 | 0.77 | PDE5A (0.89) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16216974 | 0.77 | PDE5A (0.78) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16211010 | 0.76 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16210432 | 0.76 | PDE5A (0.56) | PDE5AACHEBCHE | |
| SCHEMBL16211100 | 0.74 | PDE5A (0.82) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL30753346 | 0.74 | PDE5A (0.82) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16210663 | 0.72 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL10572862 | 0.69 | PDE5A (0.48) | PDE5AACHEBCHE | |
| SCHEMBL17792390 | 0.69 | PDE5A (1.00) | PDE5APDE6DPDE6APDE6GPDE6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
| US-20140329804-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6D 27/4885PDE6A 17/4885 |
| US-20140329804-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6D 27/4885PDE6A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.